TG Therapeutics Submits Biologics License Application to the US Food and Drug Administration for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc. announced the submission of a Biologics License Application to the FDA requesting approval of ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis.